Stock Track | HANXBIO-B Plummets 13.46% Intraday Amid Financial Losses and Lack of Commercialized Products

Stock Track2025-12-29

HANXBIO-B (03378) saw its stock price plummet by 13.46% during intraday trading on Monday, hitting a fresh low of HK$15.05. This decline represents a drop of over 50% from its initial public offering price of HK$32.

The biotechnology company, which focuses on oncology treatments, has yet to commercialize any of its products. Its core product, HX009, remains in development. Financially, HANXBIO reported net losses of RMB 85.16 million in 2023, RMB 117 million in 2024, and RMB 87.44 million for the first eight months of 2025. As of October 31, 2025, the company's cash reserves stood at RMB 133 million, while its total current liabilities were RMB 220 million, raising concerns about its financial sustainability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167947014?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167947014","market":"sg","top_or_hot":-1,"title":"Stock Track | HANXBIO-B Plummets 13.46% Intraday Amid Financial Losses and Lack of Commercialized Products","media":"Stock Track","content":"<p>HANXBIO-B (03378) saw its stock price plummet by 13.46% during intraday trading on Monday, hitting a fresh low of HK$15.05. This decline represents a drop of over 50% from its initial public offering price of HK$32.</p><p>The biotechnology company, which focuses on oncology treatments, has yet to commercialize any of its products. Its core product, HX009, remains in development. Financially, HANXBIO reported net losses of RMB 85.16 million in 2023, RMB 117 million in 2024, and RMB 87.44 million for the first eight months of 2025. As of October 31, 2025, the company's cash reserves stood at RMB 133 million, while its total current liabilities were RMB 220 million, raising concerns about its financial sustainability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HANXBIO-B Plummets 13.46% Intraday Amid Financial Losses and Lack of Commercialized Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HANXBIO-B Plummets 13.46% Intraday Amid Financial Losses and Lack of Commercialized Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-29 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HANXBIO-B (03378) saw its stock price plummet by 13.46% during intraday trading on Monday, hitting a fresh low of HK$15.05. This decline represents a drop of over 50% from its initial public offering price of HK$32.</p><p>The biotechnology company, which focuses on oncology treatments, has yet to commercialize any of its products. Its core product, HX009, remains in development. Financially, HANXBIO reported net losses of RMB 85.16 million in 2023, RMB 117 million in 2024, and RMB 87.44 million for the first eight months of 2025. As of October 31, 2025, the company's cash reserves stood at RMB 133 million, while its total current liabilities were RMB 220 million, raising concerns about its financial sustainability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1167947014","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167947014","pubTimestamp":1766988021,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HANXBIO-B (03378) saw its stock price plummet by 13.46% during intraday trading on Monday, hitting a fresh low of HK$15.05. This decline represents a drop of over 50% from its initial public offering...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"个股赛道|汉克生物-B盘中暴跌13.46%资金亏损且缺乏商业化产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"HANXBIO-B (03378) saw its stock price plummet by 13.46% during intraday trading on Monday, hitting a fresh low of HK$15.05. This decline represents a drop of over 50% from its initial public offering price of HK$32.The biotechnology company, which focuses on oncology treatments, has yet to commercialize any of its products. Its core product, HX009, remains in development. Financially, HANXBIO reported net losses of RMB 85.16 million in 2023, RMB 117 million in 2024, and RMB 87.44 million for the first eight months of 2025. As of October 31, 2025, the company's cash reserves stood at RMB 133 million, while its total current liabilities were RMB 220 million, raising concerns about its financial sustainability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167947014","isCrawlerRequest":true}